The HER2 Mutation in Lung Cancer Is a Big Thing, but Not So Big in Breast Cancer

My approach to TDXD pneumonitis is very similar to my approach to IO checkpoints. So I do a lot of rebiopsy from more for our clinical research and clinical trial matching point of view, but not so much for the HER2 mutation testing. With amplification, things can be a lot more heterogeneous. And it sounds like the loss of HER2 is a big thing in gastric, butNot so much in breast. Yeah, that's a great point though about the mutations. Let me ask you, maybe there's going to be a pan tumor approval of say TDXD for just HER2 mutant disease in general? That's a great question. We just completed